Namaste! Ek professional Equity Research Analyst ke taur par, maine Sagility India Limited ka deep fundamental analysis kiya hai. Kyunki yeh company haal hi me (November 2024) stock market me list hui hai, iska historical data largely DRHP (Draft Red Herring Prospectus) aur latest quarterly results par based hai.
Niche di gayi report Screener.in, Yahoo Finance, aur Exchange Filings ke latest verified data (as of Jan 2025) ke aadhar par banayi gayi hai.
📑 Equity Research Report: Sagility India Ltd.
1️⃣ Business Model & Work (Kya karti hai company?)
Sagility India ek pure-play Healthcare Service Provider hai jo mainly US market ko target karti hai. Yeh company technology-enabled business process management (BPM) services provide karti hai.
- Core Business:
- Payers (Insurers): US Health Insurance companies ke liye claims processing, member enrollment, payment integrity aur clinical management ka kaam karti hai.
- Providers (Hospitals/Doctors): Hospitals ke liye Revenue Cycle Management (RCM) – yaani patient billing, coding, aur payment collection manage karna.
- Revenue Source: Company ka 100% Revenue (approx) healthcare segment se aata hai.
- Geographic Exposure: Dominant US Exposure. Company ka lagbhag 90%+ revenue USA se aata hai. Baaki Jamaica, Philippines aur India se delivery centers operate hote hain.
- Competitive Advantage: Sagility sirf healthcare par focused hai (“Pure Play”), jabki competitors (jaise WNS, Infosys) ke paas mixed portfolio hota hai. Isse inhein domain expertise milti hai.
2️⃣ Industry & Sector Analysis
- Sector: IT-enabled Services (ITeS) / BPM (Healthcare Focus).
- Status: Secular Growth. US Healthcare market duniya ka sabse bada aur complex market hai.
- Growth Drivers:
- US Aging Population: Jaise-jaise US population old ho rahi hai, healthcare transactions badh rahe hain.
- Cost Pressure: US hospitals aur insurers par cost kam karne ka pressure hai, jiske karan wo India outsourcing badha rahe hain.
- Regulations: US healthcare rules (CMS updates) complex hain, jiske liye specialist help chahiye.
- Major Competitors:
- Accenture, Cognizant (IT Giants)
- ExlService, WNS (Listed in US)
- Firstsource Solutions (Listed in India – Direct Peer)
3️⃣ Latest Financial Performance (Strict Data)
Note: Kyunki company Nov 2024 me list hui hai, hamare paas limited public history hai. Data FY24 aur H1 FY25 (Apr-Sept 2024) par focus karega.
Source: Screener.in / Exchange Filings (Consolidated)
| Metrics | FY 2022 | FY 2023 | FY 2024 | TTM (Trailing 12M) |
| Revenue (Cr) | ₹ 2,833 | ₹ 4,218 | ₹ 4,753 | ~ ₹ 5,000+ (Est) |
| Op. Profit (EBITDA) | ₹ 628 | ₹ 974 | ₹ 1,085 | ₹ 1,150+ |
| OPM % | 22% | 23% | 23% | 22-23% |
| Net Profit (PAT) | ₹ 219 | ₹ 144 | ₹ 228 | ₹ 250+ |
| EPS (₹) | 0.47 | 0.31 | 0.49 | ~0.55 |
Key Financial Observations:
- Revenue Trend: Consistent growth dikh rahi hai. FY22 se FY24 tak revenue significant jump hua hai (partly due to acquisitions).
- Margins: Operating Margins (EBITDA) 23% ke aas-paas stable hain, jo industry average se behtar hain.
- Profitability Issue: Net Profit (PAT) margins kam hain (approx 5%). Iska main kaaran high Amortization costs (intangible assets write-off) aur interest cost hai jo previous acquisitions se juda hai.
- Debt: Reserves strong hain, lekin company par goodwill aur intangible assets ka heavy load hai balance sheet par.
4️⃣ Management & Shareholding (Latest Available)
Source: BSE/NSE Shareholding Pattern (Post-IPO)
- Promoters: Sagility B.V. (Affiliate of EQT Private Capital Asia). Yeh ek Private Equity backed company hai.
- Promoter Holding:~82.74% (Very High).
- Note: SEBI rules ke mutabik, promoters ko 3 saal ke andar holding 75% tak laani hogi. Future me OFS (Offer for Sale) aa sakta hai.
- FIIs/DIIs:
- IPO ke dauran strong institutional interest dekha gaya tha.
- Latest detailed breakup abhi update ho raha hai, lekin Anchor investors me Government Pension Fund Global aur kayi Mutual Funds shamil the.
- Management Quality: Experienced management hai jo pehle Hinduja Global Solutions (HGS) ke healthcare division ka hissa the. Governance ab tak stable dikh rahi hai.
5️⃣ Valuation (Latest Market Data)
Values based on approx CMP of ₹34 – ₹38 range (January 2025 Data).
| Metric | Sagility India | Firstsource Sol. (Peer) |
| P/E Ratio | ~65x – 70x | ~25x – 30x |
| EV / EBITDA | ~18x – 20x | ~14x |
| Price / Book | ~2.5x | ~4.5x |
| Market Cap | ~ ₹38,000 Cr | ~ ₹22,000 Cr |
Valuation Analysis:
- Expensive on P/E: P/E ratio bahut high dikh raha hai (~70x). Lekin yeh misleading ho sakta hai kyunki company ka PAT (Net Profit) high amortization (non-cash expense) ki wajah se depressed hai.
- Better Metric (EV/EBITDA): Agar EBITDA basis par dekhein, toh valuation thoda reasonable lagta hai (approx 18x), lekin abhi bhi apne peers (Firstsource) se mehnga (premium) trade kar raha hai.
- Fair Value View: Market isko “High Growth” aur “Specialized Player” ka premium de raha hai.
6️⃣ Future Growth Triggers (3–5 Years)
- New Client Wins (Logos): Company aggressive tareeke se US me naye Payers aur Providers ko onboarding kar rahi hai.
- Tech Integration: AI aur Automation ka use karke employee cost kam karna aur margins improve karna.
- Inorganic Growth (M&A): EQT backing hone ki wajah se, company future me chhoti US-based healthcare tech companies ko acquire kar sakti hai.
- Debt Reduction: IPO se paisa company ke paas nahi aaya (OFS tha), lekin internal accruals se debt kam hone par PAT badhega.
7️⃣ Present Situation (Current Outlook)
- Stock Phase: Discovery & Consolidation. Listing ke baad stock apni sahi price range dhoond raha hai. IPO price (₹30) ke aas-paas support leta dikh raha hai.
- Result Impact: Latest quarterly results me revenue growth steady thi, koi negative surprise nahi tha.
- Outlook: Short-term me stock range-bound reh sakta hai jab tak next quarter ke results me earnings growth confirm nahi hoti.
8️⃣ Risk & Red Flags 🚩
- Client Concentration: Top 5 clients se company ka ~50-60% revenue aata hai. Agar ek bhi bada client gaya, toh heavy loss ho sakta hai.
- Geographic Risk: 90% business USA se hai. US me regulatory changes (healthcare policies) ya Visa norms ka seedha asar padega.
- Promoter Overhang: Promoter holding 82% hai. Aane wale waqt me unhein stake bechna padega (supply pressure aayega).
- Forex Risk: Earning USD me hai aur kharcha INR/PHP me. Currency fluctuation margin ko hurt kar sakta hai.
9️⃣ Final Verdict
- Summary: Sagility India ek niche (specialized) player hai jo US Healthcare BPM sector me strong position rakhta hai. Revenue growth aur Operating Margins healthy hain, lekin reported Net Profit abhi accounting adjustments ki wajah se kam dikh raha hai.
- For Long-Term Investors: Suitable. US Healthcare ek defensive aur growing sector hai. Agar aap 3-5 saal hold kar sakte hain, toh yeh stock portfolio me stability la sakta hai.
- For Aggressive Investors: Valuation abhi thoda stretch lag raha hai (high PE). Dips (girawat) ka intezaar karna behtar hoga.
- Conservative Investors: Avoid karein. Abhi listing nayi hai aur valuation establish hona baaki hai. Firstsource Solutions (FSL) ek established alternative ho sakta hai.
Approx Target Range (1 Year): ₹42 – ₹48 (Subject to maintaining 12-15% Revenue Growth).
Stop Loss Area: ₹28 (Below IPO Price).
Disclaimer: Ye article sirf educational purpose ke liye hai. Kisi bhi nivesh se pehle apne Financial Advisor se salah zarur lein.